• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项比较化疗加放疗与化疗加手术加放疗用于局部晚期可切除下咽癌的随机试验的最终结果。

Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas.

作者信息

Beauvillain C, Mahé M, Bourdin S, Peuvrel P, Bergerot P, Rivière A, Vignoud J, Deraucourt D, Wesoluch M

机构信息

Department of Head and Neck Surgery, C.H.U., Nantes, France.

出版信息

Laryngoscope. 1997 May;107(5):648-53. doi: 10.1097/00005537-199705000-00017.

DOI:10.1097/00005537-199705000-00017
PMID:9149168
Abstract

After neoadjuvant chemotherapy, a routine conservative approach followed by salvage surgery was evaluated in terms of local control and survival in cases of advanced potentially resectable hypopharyngeal carcinoma. Between 1985 and 1989, 92 patients with T3 or T4-NO,N3 operable squamous cell hypopharyngeal carcinomas received three courses of neoadjuvant chemotherapy every 2 weeks involving a combination of cisplatin, 100 mg/m2, on day 1 and fluorouracil, 1 g/m2, on days 2 to 5, followed by total laryngopharyngectomy plus postoperative radiotherapy in 47 patients (arm A) or radiotherapy alone in 45 patients (arm B). Randomization was always performed prior to chemotherapy. The response rates of tumor and node to chemotherapy were, respectively, 67% in arm A versus 79% in arm B (P > 0.05) and 54% in arm A versus 73% in arm B (P > 0.05). Grade III or IV toxicity was similar, affecting 15% of patients and 7% of cycles in arm A versus 16% of patients and 6% of cycles in arm B. After a mean follow-up of 92 months, survival was statistically better (P = 0.04) in arm A (5-year overall survival, 37%; median survival, 40 months) than in arm B (19% and 20 months) because of a better local control rate (63% versus 39%; P < 0.01). Better results were obtained for mutilant surgery in terms of local control and overall survival, regardless of response to neoadjuvant chemotherapy.

摘要

在新辅助化疗后,对晚期潜在可切除下咽癌患者采用常规保守治疗方法后行挽救性手术的局部控制率和生存率进行了评估。1985年至1989年期间,92例T3或T4-NO、N3期可手术切除的下咽鳞状细胞癌患者每2周接受3个疗程的新辅助化疗,化疗方案为第1天顺铂100mg/m²联合第2至5天氟尿嘧啶1g/m²,随后47例患者接受全喉咽切除术加术后放疗(A组),45例患者仅接受放疗(B组)。随机分组总是在化疗前进行。A组和B组肿瘤及淋巴结对化疗的缓解率分别为67%对79%(P>0.05)和54%对73%(P>0.05)。III级或IV级毒性反应相似,A组15%的患者和7%的化疗周期出现该反应,B组为16%的患者和6%的化疗周期出现该反应。平均随访92个月后,A组的生存率在统计学上显著更好(P=0.04)(5年总生存率,37%;中位生存期,40个月),高于B组(19%和20个月),这是因为A组的局部控制率更高(63%对39%;P<0.01)。无论新辅助化疗的反应如何,挽救性手术在局部控制和总生存方面均取得了更好的结果。

相似文献

1
Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas.一项比较化疗加放疗与化疗加手术加放疗用于局部晚期可切除下咽癌的随机试验的最终结果。
Laryngoscope. 1997 May;107(5):648-53. doi: 10.1097/00005537-199705000-00017.
2
Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.顺铂和5-氟尿嘧啶诱导化疗后序贯放化疗或单纯放疗治疗喉和下咽局部晚期可切除癌:45例患者的单中心研究结果
Head Neck. 2005 Jan;27(1):15-21. doi: 10.1002/hed.20107.
3
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.诱导化疗(IC)加放疗(RT)与西妥昔单抗加 IC 和 RT 联合治疗仅可全喉切除术切除的晚期喉/下咽癌:DeLOS-II 喉器官保存试验的最终结果。
Ann Oncol. 2018 Oct 1;29(10):2105-2114. doi: 10.1093/annonc/mdy332.
4
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.一项III期研究,比较顺铂联合氟尿嘧啶与紫杉醇、顺铂和氟尿嘧啶诱导化疗,随后进行同步放化疗用于局部晚期头颈癌的疗效。
J Clin Oncol. 2005 Dec 1;23(34):8636-45. doi: 10.1200/JCO.2004.00.1990. Epub 2005 Nov 7.
5
Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.梨状窦癌的喉保留:欧洲癌症研究与治疗组织III期试验的初步结果。欧洲癌症研究与治疗组织头颈癌合作组
J Natl Cancer Inst. 1996 Jul 3;88(13):890-9. doi: 10.1093/jnci/88.13.890.
6
Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer. A long-term follow-up report.诱导化疗加放射治疗用于晚期头颈癌喉保留替代喉切除术。一项长期随访报告。
Am J Clin Oncol. 1991 Aug;14(4):273-9. doi: 10.1097/00000421-199108000-00001.
7
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.TAX 324研究中局部晚期喉癌和下咽癌亚组的序贯治疗:生存、手术及器官保留情况
Ann Oncol. 2009 May;20(5):921-7. doi: 10.1093/annonc/mdn752. Epub 2009 Jan 29.
8
Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.诱导化疗联合顺铂或西妥昔单抗同期放化疗治疗喉/下咽癌:TREMPLIN 随机 GORTEC 试验的长期结果。
Eur J Cancer. 2020 Jul;133:86-93. doi: 10.1016/j.ejca.2020.04.009. Epub 2020 May 23.
9
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.对于口咽和下咽局部晚期鳞状细胞癌,在进行根治性放化疗后进行计划中的再分期和早期手术挽救的生存影响。
Am J Clin Oncol. 2005 Aug;28(4):385-92. doi: 10.1097/01.coc.0000162422.92095.9e.
10
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.关于喉保留的3期随机试验:序贯化疗与放疗对比交替化疗与放疗。
J Natl Cancer Inst. 2009 Feb 4;101(3):142-52. doi: 10.1093/jnci/djn460. Epub 2009 Jan 27.

引用本文的文献

1
Prognostic Factors and Long-Term Outcome Prediction in Patients with Hypopharyngeal Carcinoma Treated with (Chemo)radiotherapy: Development of a Prognostic Model.下咽癌患者接受(化疗)放疗后的预后因素及长期结局预测:一种预后模型的建立
Biomedicines. 2025 Feb 9;13(2):417. doi: 10.3390/biomedicines13020417.
2
Upfront Surgery Versus Upfront Concurrent Chemoradiotherapy as Primary Modality in Hypopharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. upfront 手术与 upfront 同期放化疗作为下咽鳞癌的主要治疗方式:系统评价和荟萃分析。
J Otolaryngol Head Neck Surg. 2024 Jan-Dec;53:19160216241293633. doi: 10.1177/19160216241293633.
3
Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma.
下咽癌不同治疗方式及临床分期的生存分析
Front Oncol. 2023 Mar 3;13:1109417. doi: 10.3389/fonc.2023.1109417. eCollection 2023.
4
Treatment options for resectable hypopharyngeal squamous cell carcinoma: A systematic review and meta-analysis of randomized controlled trials.可切除下咽鳞状细胞癌的治疗选择:一项随机对照试验的系统评价和荟萃分析。
PLoS One. 2022 Nov 29;17(11):e0277460. doi: 10.1371/journal.pone.0277460. eCollection 2022.
5
Distinct Failure Patterns in Hypopharyngeal Cancer Patients Receiving Surgery-Based Versus Radiation-Based Treatment.接受以手术为基础治疗与以放疗为基础治疗的下咽癌患者具有不同的失败模式。
Ann Surg Oncol. 2023 Feb;30(2):1169-1181. doi: 10.1245/s10434-022-12744-1. Epub 2022 Nov 6.
6
Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy.通过选择局部晚期头颈癌患者进行质子图像引导放疗以实现治疗剂量递增[PIRATES]:一项MRI引导的自适应粒子放疗的I期安全性和可行性试验
Clin Transl Radiat Oncol. 2021 Nov 11;32:35-40. doi: 10.1016/j.ctro.2021.11.003. eCollection 2022 Jan.
7
Surgical approach of laryngofissure combined with epiglottis valley in treating locally-advanced pyriform sinus carcinoma.喉裂开联合会厌谷入路治疗局部晚期梨状窝癌
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Aug 28;46(8):843-850. doi: 10.11817/j.issn.1672-7347.2021.200996.
8
Treatment patterns and survival outcomes of advanced hypopharyngeal squamous cell carcinoma.晚期下咽鳞状细胞癌的治疗模式和生存结果。
World J Surg Oncol. 2020 May 1;18(1):82. doi: 10.1186/s12957-020-01866-z.
9
Management of Advanced-stage Hypopharyngeal Carcinoma: 25-Year Experience from a Tertiary Care Medical Center.晚期下咽癌的管理:来自三级医疗中心的25年经验
Cureus. 2020 Jan 16;12(1):e6679. doi: 10.7759/cureus.6679.
10
Comparative efficacy of six therapies for Hypopharyngeal and laryngeal neoplasms: a network meta-analysis.比较 6 种疗法治疗下咽和喉肿瘤的疗效:网状荟萃分析。
BMC Cancer. 2019 Mar 29;19(1):282. doi: 10.1186/s12885-019-5412-z.